Can a video game-based 'digital medicine' help children with autism and co-occurring ADHD?
CHOP researchers evaluate feasibility, safety and benefit potential of project: EVO Platform
Philadelphia, January 3, 2019–Researchers at Children’s Hospital of Philadelphia (CHOP) evaluated a digital medicine tool designed as an investigational treatment for children with autism spectrum disorder (ASD) and co-occurring attention/deficit-hyperactivity disorder (ADHD).
The results of the study, published in the Journal of Autism and Developmental Disorders, confirmed the acceptability, feasibility, and safety of Project: EVO, which delivers sensory and motor stimuli through an action video game experience, designed by Akili Interactive, a prescription digital medicine company.
As many as 50 percent of children with ASD have some ADHD symptoms, with roughly 30 percent receiving a secondary diagnosis of ADHD. However, since ADHD medications are less effective in children with both disorders than in those with only ADHD, researchers are exploring alternative treatments.
Children with ASD and ADHD symptoms are also at high risk for impaired “cognitive function,” including the brain’s ability to maintain attention and focus on goals while ignoring distractions. As children reach school age and beyond, these cognitive impairments make it more difficult for them to set and achieve goals, as well as successfully navigate the demands of day-to-day life in the community.
“Our study showed that children engaged with the Project: EVO treatment for the recommended amount of time, and that parents and children reported high rates of satisfaction with the treatment,” Benjamin Yerys, Ph.D., a child psychologist at CHOP’s Center for Autism Research (CAR) and first and corresponding author on the study. “Based on the promising study results, we look forward to continuing to evaluate the potential for Project: EVO as a new treatment option for children with ASD and ADHD.”
The feasibility study was conducted by a team of researchers at CAR in collaboration with Akili. The study included 19 children aged 9-13 diagnosed with ASD and co-occurring ADHD symptoms. Participants in the study were given either the Project: EVO treatment, which is delivered via an action video game experience, or an educational activity involving pattern recognition. The primary outcome measure for efficacy was the TOVA API, an FDA-cleared objective measure of attention. Key secondary outcome measures were caregiver reports of ADHD symptoms and the ability of the child to plan and complete tasks, as well as a cognitive test battery assessing working memory.
The study found that children adhered to the treatment protocol by engaging with the treatment for 95 percent or more of the recommended treatment sessions. Both parents and children reported that the treatment had value for improving a child’s ability to pay attention and served as a worthwhile approach for treatment. The study also found that after using Project: EVO, children showed a trend toward improved attention on the TOVA API score, and they showed general ADHD symptom improvement based on parent reports. Though the sample size of the study was small, the study showed that using Project: EVO was feasible and acceptable with potentially therapeutic effects. The research team is planning a larger follow-up study for continued evaluation of Project: EVO’s potential efficacy.
This study was sponsored by Akili Interactive, which provided financial support to Dr. Yerys and co-author Jennifer Bertollo. All other authors were advisers to Akili and participated in study design, data interpretation and manuscript preparation. Co-author Robert Schultz holds stock options for consulting work to Akili, and is also a member of the Scientific Advisory Board of Akili. Co-author Geraldine Dawson is on the Scientific Advisory Board of Akili. Akili participated in the study design but did not participate in the data analysis, manuscript preparation or decision to publish.
Yerys et al, “Pilot study of a novel interactive digital treatment to improve cognitive control in children with autism spectrum disorder and co-occurring attention symptoms,” J Autism Dev Disord, online December 20, 2018.
About Children’s Hospital of Philadelphia: Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children’s Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 546-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.
About Akili: Akili is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. Akili is pioneering the development of digital treatments with direct therapeutic activity, delivered not through a pill but through a high-quality action video game experience. Akili is advancing a broad pipeline of programs to treat cognitive deficiency and improve symptoms associated with medical conditions across neurology and psychiatry, including ADHD, MDD, ASD and various inflammatory diseases. Akili is also developing complementary and integrated clinical monitors and measurement-based care applications. The Company was co-founded by PureTech Health (PRTC.L) and is a founding member of the Digital Therapeutics Alliance. For more information on Akili, please visit: http://www.